EXOSOME-BASED LIQUID BIOPSY
Craif is a pioneer in exosome-based liquid biopsy for accurate and unpainful early cancer detection.
We aim to create a society where everyone can stay healthy throughout their lifetime.
Craif present results of urine-based urothelial cancer detection at the American Association of Cancer Research (AACR) Annual Meeting 2021
Craif Inc. Announces Residency at JLABS @ Shanghai To Further Accelerate the Development of an Innovative Exosome Biomarker Discovery Platform
Craif’s Research Project Selected to be Funded by Japan Agency for Medical Research and Development (AMED) to Accelerate Development of Urine-based, Highly Accurate Early Cancer Diagnosis
Icaria Inc. Announces Closing of Series A Funding Round and Company Name Change to “Craif Inc.”
Enrichment of exosomes from body fluid efficiently with a simple procedure allows a more accurate interpretation of cellular communications